CUV and UR9 Related Headlines

Go Back

Aug 27, 2026 01:42AM A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Jul 23, 2026 12:10AM CLINUVEL implements strategic reorganisation to refocus on U.S. markets

Jul 20, 2026 01:37AM CLINUVEL’s ADS to commence trading on Nasdaq

Jul 13, 2026 01:10AM SCENESSE® approved for EPP in Canada

Apr 24, 2026 01:47AM CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study

Apr 15, 2026 02:18AM CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026

Sep 28, 2025 10:56PM CLINUVEL to advance novel pharmaceutical formulations in preclinical program

CUV and UR9 Related Press Releases

Go Back

Aug 27, 2026 01:42AM A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

Jul 23, 2026 12:10AM CLINUVEL implements strategic reorganisation to refocus on U.S. markets

Jul 20, 2026 01:37AM CLINUVEL’s ADS to commence trading on Nasdaq

Jul 13, 2026 01:10AM SCENESSE® approved for EPP in Canada

Apr 24, 2026 01:47AM CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study

Apr 15, 2026 02:18AM CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026

Sep 28, 2025 10:56PM CLINUVEL to advance novel pharmaceutical formulations in preclinical program

CUV and UR9 Related SEC Filings

Go Back